Paradigm Biopharmaceuticals logo

Paradigm Biopharmaceuticals(ASX) PAR

Market CapA$153.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-30%
5 Year-87%
1 Year-13%
1 Month+44%
A$0.25
-2.00%
-0.01Today
Paradigm Biopharmaceuticals last closing stock price
MetricPriceDate
Last closeAUD 0.252026-09-18
Paradigm Biopharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.08%AUD 0.242026-09-11
1 month+44.12%AUD 0.172026-08-19
3 month+44.12%AUD 0.172026-06-19
Year to date-27.94%AUD 0.342025-12-31
1 year-12.5%AUD 0.282025-09-18
3 year-63.7%AUD 0.682023-09-19
5 year-86.54%AUD 1.822021-09-17
Since inception-29.77%AUD 0.352015-08-19

Paradigm Biopharmaceuticals Financials at a Glance

Market Cap

A$153.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$132.27K

Net Income (TTM)

-A$75.10M

EPS (TTM)

-A$0.15

P/E Ratio

-1.61

Dividend

A$0.00

Beta (Volatility)

0.02 (Low)

Price

A$0.25

Volume

0

Open

A$0.26

Previous Close

A$0.25

Daily Range

A$0.25 - A$0.27

52-Week Range

A$0.14 - A$0.47

Estimated Earnings Date

Feb 24, 2027

PAR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited is a biotechnology company based in Melbourne, Australia, focused on repurposing existing drugs to develop therapeutic solutions for various health conditions. The company is primarily known for its injectable formulation of pentosan polysulfate sodium, which is currently in development for treating osteoarthritis, mucopolysaccharidosis, and other conditions.

Products and Services
  • Injectable formulation of pentosan polysulfate sodium
  • Therapeutic solutions for osteoarthritis and mucopolysaccharidosis
  • Research and development in viral infections and acute respiratory distress syndrome
Growth Outlook
  • Strong pipeline with multiple therapeutic applications in development
  • Increasing demand for innovative treatments in the healthcare sector
  • Potential for strategic partnerships to enhance market reach
Financial Highlights
  • Recent quarterly revenue of AUD 55,000, showing growth potential
  • Trailing twelve months (TTM) revenue of AUD 1.1 million, indicating market interest
  • Cash and cash equivalents of AUD 15.4 million, providing operational stability
Paradigm Biopharmaceuticals Limited operates in a dynamic sector with a focus on innovative drug repurposing. The company’s primary product, pentosan polysulfate sodium, is being developed for various conditions, which could lead to significant market opportunities. The growth outlook is bolstered by a strong pipeline and the potential for strategic partnerships, which may enhance the company's market presence. Financially, the company has shown a recent increase in revenue, alongside a solid cash position, which supports ongoing research and development efforts. This combination of innovative products and financial stability positions Paradigm Biopharmaceuticals as a noteworthy player in the biotechnology industry.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Paul John Rennie

Website

www.paradigmbiopharma.com

Headquarters

Melbourne, VIC 3000, AU

PAR Financials

Key Financial Metrics (TTM)

Gross Margin

-102.76%

Operating Margin

-76246.47%

Net Income Margin

-70282.28%

Return on Equity

-1189.87%

Return on Capital

-556.54%

Return on Assets

-184.36%

Earnings Yield

-62.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$153.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

626.43M

Volume

0

Avg. Volume

1.88M

Financials (TTM)

Gross Profit

-A$130.79K

Operating Income

-A$84.26M

EBITDA

-A$86.20M

Operating Cash Flow

-A$59.68M

Capital Expenditure

A$43.69M

Free Cash Flow

-A$15.99M

Cash & ST Invst.

A$15.44M

Total Debt

A$7.51M

Paradigm Biopharmaceuticals Performance Analysis

Paradigm Biopharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 46,760-41.0%
20242024-06-30AUD 65,80040.7%
20252025-06-30AUD 52,120-20.8%
20262026-06-30AUD 80,15053.8%
Paradigm Biopharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-74.6%
Q42025-06-30112.1%
Q22025-12-31-29.0%
Q42026-06-30118.7%
Paradigm Biopharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.1810.0%
20242024-06-30AUD -0.2011.7%
20252025-06-30AUD -0.06-70.2%
20262026-06-30AUD -0.15154.9%
Paradigm Biopharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3150.6%
Q42025-06-30-97.6%
Q22025-12-31-70.3%
Q42026-06-30-71.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$55.00K

-16.4%

Gross Profit

-A$31.20K

-124.0%

Gross Margin

-56.72%

N/A

Market Cap

A$153.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$12.79M

N/A

Employees

12

N/A

Net Income

-A$33.09M

-241.3%

EBITDA

-A$39.20M

-163.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$15.44M

-13.6%

Total Debt

A$7.51M

+3037.8%

Accounts Receivable

A$13.06M

+157.0%

Inventory

A$0.00

N/A

Long Term Debt

A$361.69K

+207.9%

Short Term Debt

A$7.15M

+5766.7%

Return on Assets

-1.84%

N/A

Return on Invested Capital

-15.39%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$24.04M

-61.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EMV.AXEMVision Medical Devices Ltd
A$1.67+0.00%
NYR.AXNyrada Inc.
A$0.48-1.04%
ONE.AXOneview Healthcare PLC
A$0.13-7.14%
ACW.AXActinogen Medical Limited
A$0.05-1.82%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About PAR

What is the current price of Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals is trading at A$0.25 per share.

What is the 52-week range for Paradigm Biopharmaceuticals?

Over the past 52 weeks, Paradigm Biopharmaceuticals has traded between A$0.14 and A$0.47.

How much debt does Paradigm Biopharmaceuticals have?

As of the most recent reporting period, Paradigm Biopharmaceuticals reported total debt of A$7.51M.

How much cash does Paradigm Biopharmaceuticals have on hand?

Paradigm Biopharmaceuticals reported A$15.37M in cash and cash equivalents in its most recent financial results.

What is Paradigm Biopharmaceuticals’s dividend yield?

Paradigm Biopharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services